Embolotherapy for Neuroendocrine Tumor Liver Metastases: Prognostic Factors for Hepatic Progression-Free Survival and Overall Survival.

Abstract

The purpose of the study was to evaluate prognostic factors for survival outcomes following embolotherapy for neuroendocrine tumor (NET) liver metastases. This was a multicenter retrospective study of 155 patients (60years mean age, 57% male) with NET liver metastases from pancreas (n=71), gut (n=68), lung (n=8), or other/unknown (n=8) primary sites treated with conventional transarterial chemoembolization (TACE, n=50), transarterial radioembolization (TARE, n=64), or transarterial embolization (TAE, n=41) between 2004 and 2015. Patient-, tumor-, and treatment-related factors were evaluated for prognostic effect on hepatic progression-free survival (HPFS) and overall survival (OS) using unadjusted and propensity score-weighted univariate and multivariate Cox proportional hazards models. Median HPFS and OS were 18.5 and 125.1months for G1 (n=75), 12.2 and 33.9months for G2 (n=60), and 4.9 and 9.3months for G3 tumors (n=20), respectively (p<0.05). Tumor burden>50% hepatic volume demonstrated 5.5- and 26.8-month shorter median HPFS and OS, respectively, versus burden≤50% (p<0.05). There were no significant differences in HPFS or OS between gut or pancreas primaries. In multivariate HPFS analysis, there were no significant differences among embolotherapy modalities. In multivariate OS analysis, TARE had a higher hazard ratio than TACE (unadjusted Cox model: HR 2.1, p=0.02; propensity score adjusted model: HR 1.8, p=0.11), while TAE did not differ significantly from TACE. Higher tumor grade and tumor burden prognosticated shorter HPFS and OS. TARE had a higher hazard ratio for OS than TACE. There were no significant differences in HPFS among embolotherapy modalities.